NCT03922711

A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

A Double-Blind, Randomized, Three-Arm, Parallel-Group Study to Assess the Efficacy and Safety of Two Doses of Pridopidine Versus Placebo for the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease (gLIDe)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Prilenia · Industry
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs. placebo for the treatment of Levodopa Induced Dyskinesia (LID) in patients with Parkinson Disease.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Pridopidine	Oral capsule
DRUG	Placebo	Oral capsule

Timeline

• Start date: 2019-05-22
• Primary completion: 2020-07-22
• Completion: 2020-07-22
• First posted: 2019-04-22
• Last updated: 2022-07-01
• Results posted: 2022-07-01

Locations

33 sites across 1 country: United States

Regulatory

• FDA-regulated drug study